Blood And Lymphatic Cancer-targets And Therapy

Blood And Lymphatic Cancer-targets And Therapy

血液和淋巴系统癌症-靶点和治疗

  • 3区 中科院分区
  • Q2 JCR分区

期刊简介

《Blood And Lymphatic Cancer-targets And Therapy》是由Dove Medical Press出版社创办的英文国际期刊(ISSN: 1179-9889),该期刊长期致力于肿瘤学领域的创新研究,主要研究方向为ONCOLOGY。作为SCIE收录期刊(JCR分区 Q2,中科院 3区),本刊采用OA未开放获取模式(OA占比1%),以发表肿瘤学领域等方向的原创性研究为核心(研究类文章占比82.35%%)。凭借严格的同行评审与高效编辑流程,期刊年载文量精选控制在17篇,确保学术质量与前沿性。成果覆盖Web of Science等国际权威数据库,为学者提供推动医学领域高水平交流平台。

投稿咨询

投稿提示

Blood And Lymphatic Cancer-targets And Therapy审稿周期约为16 Weeks。该刊近年未被列入国际预警名单,年发文量约17篇,录用竞争适中,主题需确保紧密契合医学前沿。投稿策略提示:避开学术会议旺季投稿以缩短周期,语言建议专业润色提升可读性。

  • 医学 大类学科
  • English 出版语言
  • 是否预警
  • SCIE 期刊收录
  • 17 发文量

中科院分区

《新锐期刊分区表》(2026年3月发布)

Top期刊 综述期刊 大类学科 小类学科
医学
3区
ONCOLOGY 肿瘤学
3区

期刊分区表(2025年3月升级版)

Top期刊 综述期刊 大类学科 小类学科
医学
2区
ONCOLOGY 肿瘤学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY ESCI Q2 161 / 333

51.8

学科:ONCOLOGY ESCI Q3 181 / 333

45.8

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY ESCI Q1 73 / 328

77.9

学科:ONCOLOGY ESCI Q3 184 / 328

44.05

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY ESCI Q2 99 / 322

69.4

学科:ONCOLOGY ESCI Q3 188 / 322

41.77

期刊发文

  • Prognostic Value of the Aggregate Inflammation Systemic Index (AISI) in Patients with Diffuse Large B-Cell Lymphoma: A Multicenter Retrospective Stud

    Author: Chen, Xicheng; Huang, Linyu; Zhang, Qiming; Xing, Xing; Zhang, Shuo; Wang, Chunling; Wang, Ling; Shen, Ziyuan; Sang, Wei

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S571663

  • Construction and Validation of an N7-Methylguanosine-Related Prognostic Model for Acute Myeloid Leukemi

    Author: Wang, Lina; Li, Ming; Xi, Yaming

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S575337

  • Crosstalk Between FOXN3 and E2F5 Reveals a Novel Tumor Suppressive Pathway in Acute Myeloid Leukemia via MAPK Signaling: Implications for Potential Future Targeted Therap

    Author: Zhang, Jinjing; Jiang, Qiao; Liu, Tong; Li, Hong; Liang, Ying; Lu, Xianglan; Pang, Hui; Li, Shibo; Li, Yan; Zhang, Rui

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S571966

  • Safety and Efficacy of Flumatinib in Patients with Chronic Phase Chronic Myeloid Leukemia: A Real-Life Cohort Observational Stud

    Author: Cheng, Fang; Cui, Zheng; Li, Qiang; Wang, Liu; Li, Weiming

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S573070

  • Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic lymphohistiocytosis-a Rare and Dangerous Diseas

    Author: Meng, Guangqiang; Wang, Manzhi; Sun, Congcong; Feng, Gege; Ren, Jing; Feng, Saran; Wang, Yan

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S574445

  • Global Patterns, Temporal Trends, and Potential Non-Infectious Risk Factors for Burkitt Lymphoma from 1990 to 202

    Author: Jin, Shi-Kai; Lyu, Jun-Ting; Feng, Zi-Yu; Zhang, Shu-Qi; Lu, Bin-Yan; Yan, Qin-Fu; Li, Jing; Du, Jun; Huang, Zou-Fang

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. 1-12. DOI: 10.2147/BLCTT.S556459

  • Study on the Role of Neutrophil Extracellular Traps-Based Risk Model and Discriminative Gene LTF in the Prognosis of Acute Myeloid Leukemia and the Regulation of Immune Microenvironmen

    Author: Li, Yongjian; Zhang, Jingru; Liu, Tingting; Zhang, Di; Wang, Nana; Liu, Xiaomin; Feng, Panpan; Zhang, Juan; Ji, Chunyan; Ye, Jingjing

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2026; Vol. 16, Issue , pp. -. DOI: 10.2147/BLCTT.S562651

  • A Monocyte-Driven Prognostic Model for Multiple Myeloma: Multi-Omics and Machine Learning Insight

    Author: Xie, Linzhi; Gao, Meng; Tan, Shiming; Zhou, Yi; Liu, Jing; Wang, Liwen; Li, Xin

    Journal: BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY. 2025; Vol. 15, Issue , pp. 21-37. DOI: 10.2147/BLCTT.S517354